Dr. Manal Elnenaei, MBChB, MSc, PhD, FRCPath
Chief of Service in Clinical Chemistry, NSHA; Associate Professor, Dalhousie University
Nova Scotia Health Authority; Dalhousie University, Halifax, NS.
Myeloma tumor banking, Myeloma genomic and epigenomic pathways
Effect of reflexive testing on early diagnosis of pituitary disease to improve patient outcomes
Appropriate interpretation of dynamic function tests in endocrinology
Appropriate test utilization to reduce unnecessary waste to the health system
Myeloma Tumor Bank and Genomics Research
Dr. Elnenaei led the Myeloma Tumor Bank and Database initiative in 2016 and brought together a multidisciplinary team comprising Dalhousie Faculty as well Clinician Scientists (Dalhousie Myeloma Research Group), to focus on translational research in Multiple Myeloma. Objectives of this research include a joint focus on clinical genomics and immunogenomics in myeloma leveraging our unique, multidisciplinary expertise to create faithful models of cancer, establish and test new treatment modalities.
This team is currently working on novel and effective genomic diagnostic/prognostic platforms for myeloma patients to replace the more expensive outsourced FISH studies. The first phase of this project has shown promising results. Further work on specific mutation and gene expression panels will also be part of the latter as well as inform immunogenomic and other drug discovery models towards precision medicine.
Previous research that included her PhD at the Institute of Cancer Research in London, UK, focused on the genetic characterization of multiple myeloma on which she had several peer reviewed publications.
Other research projects
Dr. Elnenaei is also the lead and co-lead investigator on a number of projects within the field of endocrine medicine as well as laboratory test utilization, including physician scorecard models.
Membership Status:Dr. Manal Elnenaei is an Associate Member
Address:Department of Pathology & Laboratory Medicine, 5788 University Avenue, Room 616, Halifax, Nova Scotia, B3H 1V8
Matutes E, Parry-Jones N, Brito-Babapulle V, Wotherspoon A, Morilla R, Atkinson S, Elnenaei MO, Jain P, Giustolisi GM, A'Hern RP, Catovsky D. The leukemic presentation of mantle- cell lymphoma: disease features and prognostic factors in 58 patients. Leuk Lymphoma 2004 Oct;45:2007-15.
Elnenaei MO, Gruszka-Westwood AM, A'Hernt R, Matutes E, Sirohi B, Powles R, Catovsky D. Gene abnormalities in multiple myeloma;the relevance of TP53, MDM2, and CDKN2A. Haematologica. 2003 May;88:529-37.
Elnenaei MO, Hamoudi RA, Swansbury J, Gruszka-Westwood AM, Brito-Babapulle V, Matutes E, Catovsky D. Delineation of the minimal region of loss at 13q14 in multiple myeloma. Genes Chromosomes Cancer. 2003 Jan;36:99-106.
Elnenaei MO, Jadayel DM, Matutes E, Morilla R, Owusu-Ankomah K, Atkinson S, Titley I, Mandala EM, Catovsky D. Cyclin D1 by flow cytometry as a useful tool in the diagnosis of B-cell malignancies. Leuk Res. 2001 Feb;25:115-23.
Jain P, Giustolisi GM, Atkinson S, Elnenaei MO, Morilla R, Owusu-Ankomah K, Rafiq-Mohammed F, Matutes E, Wotherspoon A, Catovsky D. Detection of cyclin D1 in B cell lymphoproliferative disorders by flow cytometry. J Clin Pathol. 2002 Dec;55:940-5.
Brito-Babapulle V, Gruszka-Westwood AM, Platt G, Andersen CL, Elnenaei MO, Matutes E, Wotherspoon AC, Weston-Smith SG, Catovsky D.Translocation t(2;7)(p12;q21-22) with dysregulation of the CDK6 gene mapping to 7q21-22 in a non-Hodgkin's lymphoma with leukemia. Haematologica. 2002 Apr;87:357-62.
Gruszka-Westwood AM, Atkinson S, Summersgill BM, Shipley J, Elnenaei MO, Jain P, Hamoudi RA, Kaeda JS, Wotherspoon AC, Matutes E, Catovsky D. Unusual case of leukemic mantle cell lymphoma with amplified CCND1/IGH fusion gene. Genes Chromosomes Cancer. 2002 Feb;33:206-12.
Recent cancer related abstract/poster
Knopf P, Campbell C, Gaston D, Wagner J, Goudie M, Greer W, White D, Couban S, Forward N, Boudreau J, Elnenaei M. Low Pass Whole Genome Sequencing –A Novel Method for Prognostication in Multiple Myeloma. CBMTG 2018 Annual Conference, Poster 2018.